eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals."
.
she died five days after she was admitted to altnagelvin hospital following a fall at home in which she sustained a broken hip.
.738, may 18, 2018 (eat),
.